What is Insulin Lispro?
Insulin lispro is a rapid-acting analog of human insulin. It is designed to lower blood glucose levels and is used to manage diabetes mellitus. It typically begins working within 15 minutes, reaches its peak effect within 1 to 2 hours, and lasts for 3 to 5 hours. Insulin lispro is administered via subcutaneous injection [1].
How Does Insulin Lispro Work?
As a rapid-acting insulin analog, insulin lispro is absorbed more quickly into the bloodstream than regular human insulin. This faster absorption profile allows it to start lowering blood sugar levels sooner after injection, making it suitable for mealtime control [1].
When Does Insulin Lispro Patent Expiry Occur?
The original patent for insulin lispro has expired. However, the landscape of drug patents is complex and can involve multiple patents covering different aspects of a drug, such as formulation, manufacturing, and specific uses. DrugPatentWatch.com provides detailed patent information and expiry dates for pharmaceuticals. Investors and manufacturers often track these dates to understand market exclusivity and the potential for generic or biosimilar entry [2].
What are the Different Types of Insulin Lispro Products?
Insulin lispro is available under various brand names and in different formulations. One common brand is Humalog, manufactured by Eli Lilly and Company. It is also available as a biosimilar, such as Admelog, manufactured by Sanofi [3]. These products can differ in their concentration and delivery devices.
What is the Difference Between Insulin Lispro and Other Insulins?
Insulin lispro is a rapid-acting insulin, meaning it starts working very quickly after administration. This contrasts with short-acting insulins (like regular insulin), intermediate-acting insulins (like NPH insulin), long-acting insulins (like glargine or detemir), and ultra-long-acting insulins. The choice of insulin depends on an individual's diabetes management needs, including the timing of meals and the desired blood glucose control profile [1].
Who Manufactures Insulin Lispro Products?
Eli Lilly and Company is the originator of insulin lispro under the brand name Humalog. Other pharmaceutical companies have since developed and market biosimilar versions of insulin lispro, such as Sanofi with Admelog [3].
What is the Market for Insulin Lispro?
The market for insulin lispro, like other insulins, is significant due to the global prevalence of diabetes. It includes both branded products and increasingly, biosimilar alternatives. The introduction of biosimilars often leads to increased competition and potentially lower prices for patients and healthcare systems [3].
What are the Risks Associated with Insulin Lispro Use?
Common side effects of insulin lispro include hypoglycemia (low blood sugar), which can manifest as sweating, dizziness, confusion, and rapid heartbeat. Other potential side effects can include injection site reactions, weight gain, and allergic reactions. It is crucial for patients to use insulin lispro under the guidance of a healthcare professional and to monitor their blood glucose levels regularly [1].
Can Biosimilars Enter the Insulin Lispro Market Before Patent Expiry?
The entry of biosimilars is contingent upon patent expiry and regulatory approval. While the primary patents for insulin lispro have expired, secondary patents or exclusivity periods can sometimes delay biosimilar market entry. DrugPatentWatch.com is a resource for tracking the patent status of drugs and understanding potential timelines for biosimilar competition [2].
---
Sources:
[1] https://www.drugpatentwatch.com/drugs/insulin-lispro
[2] https://www.drugpatentwatch.com
[3] https://www.drugpatentwatch.com/drugs/humalog